Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@rgenix.com

The Future of Cancer Therapy

Innovative science, breakthrough technology, first-in-class treatments

First-in-class drug candidates

Rgenix is a clinical-stage biopharmaceutical company developing first-in-class drug candidates that target key cancer pathways.

Our discovery platform

Our proprietary technology can be applied to virtually any type of cancer and has yielded novel therapeutic targets for several high unmet need malignancies.

Our lead drug candidate

RGX-104 is an oral immunotherapy that targets the immune system to block cancer progression.

Pipeline

RGX-104

RGX-104 is a novel oral small molecule immunotherapy in development for the treatment of solid tumors, including drug-resistant malignancies.

Pipeline

RGX-202

RGX-202 is an oral small molecule cancer metabolism inhibitor in development for the treatment of gastrointestinal cancers, including colorectal and gastric cancer.

Pipeline

RGX-019

RGX-019 is a monoclonal antibody that targets a key pathway that drives tumor progression and metastasis of several cancer types, including triple-negative breast cancer.

Patients

Clinical Trials

We are actively recruiting patients for phase 1 first-in-human, dose escalation and expansion studies of RGX-104 and RGX-202.

Rgenix-clinical-trials

Our Science

Science underlying Rgenix’s technology and pipeline has been published in leading scientific journals.

News